ASX 200 healthcare shares performed well in 2024, with the S&P/ASX 200 Health Care Index (ASX: XHJ) rising 6.01% and delivering a 12-month total return, including dividends, of 7.51%.
However, the healthcare sector did underperform the S&P/ASX 200 Index (ASX: XJO), which rose by 7.49% (or 11.44% including dividends).
Here are the best-performing stocks of 2024 in the healthcare sector.
ASX healthcare share Sigma ripped 162% higher to close at $2.62 on 31 December.
Sigma Healthcare's share price rocketed after the company announced plans to merge with the privately owned Chemist Warehouse pharmaceutical chain. The Australian Competition & Consumer Commission (ACCC) has green-lighted the deal but it's not finalised yet. Sigma Healthcare already owns a network of chemists, including Amcal, Discount Drug Stores, and Guardian Pharmacy.
The Pro Medicus share price rose by 161% to finish the year at $250.12 per share.
The medical imaging technology company reported strong profit growth last year and won various large new contracts with hospitals and other healthcare providers keen to use its industry-leading Visage platform. One of those new contracts was a 10-year $330 million deal with Trinity Health.
The Telix Pharmaceuticals share price lifted 144.1% to close at $24.61 on 31 December.
The radiopharmaceutical company reported strong revenue growth for its Illuccix prostate cancer imaging product. Telix also expanded its US manufacturing footprint through the acquisition of RLS, America's only joint commission-accredited network, with 31 radio pharmacies serving more than 85% of the population.
In October, the United States Food and Drug Administration (FDA) accepted Telix's application for Pixclara, a PET agent for the imaging of brain cancer. Telix hopes to receive approval and launch the product in the US this year.
This ASX 200 healthcare share rocketed 120.6% to close at $4.17 on 31 December.
Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company whose products are designed to improve treatment outcomes for cancer patients.
Last year, the SECuRE therapy trial results for its prostate cancer treatment, 67Cu-SAR-bisPSMA, created much excitement, and Clarity expects to release final data this year. The first patient treated with two doses of 67Cu-SAR-bisPSMA achieved a complete response, with no detectable cancer after treatment.
The Fisher & Paykel share price ascended 60.1% to close at $34.95 per share on 31 December.
The company put in a strong financial performance last year. For the six months ended 30 September, Fisher & Paykel reported an 18% increase in operating revenue to a record of NZ$951.2 million. The healthcare provider reported strong top-line growth for both its hospital and homecare segments.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.